{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:37:41Z","timestamp":1761896261489},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,1,27]],"date-time":"2016-01-27T00:00:00Z","timestamp":1453852800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00296-016-3428-0","type":"journal-article","created":{"date-parts":[[2016,1,27]],"date-time":"2016-01-27T01:08:04Z","timestamp":1453856884000},"page":"575-578","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Drug levels, immunogenicity and assessment of active sacroiliitis in patients with axial spondyloarthritis under biologic tapering strategy"],"prefix":"10.1007","volume":"36","author":[{"given":"Miriam","family":"Almirall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Gimeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek Carlos","family":"Salman-Monte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Iniesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pilar","family":"Lisbona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Maym\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,27]]},"reference":[{"key":"3428_CR1","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187\u20131193","journal-title":"Lancet"},{"key":"3428_CR2","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D Heijde Van der","year":"2006","unstructured":"Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:2136\u20132146","journal-title":"Arthritis Rheum"},{"key":"3428_CR3","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA et al (2013) Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 72:815\u2013822","journal-title":"Ann Rheum Dis"},{"key":"3428_CR4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10067-011-1722-5","volume":"30","author":"V Navarro-Comp\u00e1n","year":"2011","unstructured":"Navarro-Comp\u00e1n V, Moreira V, Ariza-Ariza R, Hern\u00e1ndez-Cruz B, Vargas-Lebr\u00f3n C, Navarro-Sarabia F (2011) Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol 30:993\u2013996","journal-title":"Clin Rheumatol"},{"key":"3428_CR5","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3899\/jrheum.111337","volume":"39","author":"J Paccou","year":"2012","unstructured":"Paccou J, Bacl\u00e9-Boutry MA, Solau-Gervais E, Bele-Philipe P, Flipo RM (2012) Dosage adjustment of anti-tumor necrosis factor-\u03b1 inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice. J Rheumatol 39:1418\u20131423","journal-title":"J Rheumatol"},{"key":"3428_CR6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/annrheumdis-2014-205202","volume":"75","author":"J Z\u00e1vada","year":"2016","unstructured":"Z\u00e1vada J, Uher M, Sisol K, Forejtov\u00e1 S, Jaro\u0161ov\u00e1 K, Mann H et al (2016) A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1\u00a0year: a propensity score-matched cohort study. Ann Rheum Dis 75:96\u2013102","journal-title":"Ann Rheum Dis"},{"key":"3428_CR7","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3899\/jrheum.141128","volume":"42","author":"C Plasencia","year":"2015","unstructured":"Plasencia C, Kneepkens EL, Wolbink G, Krieckaert CL, Turk S, Navarro-Comp\u00e1n V et al (2015) Comparing tapering strategy to standard dosing regimen of tumor necrosis factor inhibitors in patients with spondyloarthritis in low disease activity. J Rheumatol 42:1638\u20131646","journal-title":"J Rheumatol"},{"key":"3428_CR8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2013-204185","volume":"74","author":"EL Kneepkens","year":"2015","unstructured":"Kneepkens EL, Wei JC, Nurmohamed MT, Yeo KJ, Chen CY, van der Horst-Bruinsma IE et al (2015) Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24\u00a0weeks of follow-up. Ann Rheum Dis 74:396\u2013401","journal-title":"Ann Rheum Dis"},{"key":"3428_CR9","first-page":"661","volume":"28","author":"S Arends","year":"2010","unstructured":"Arends S, Lebbink HR, Spoorenberg A, Bungener LB, Roozendaal C, van der Veer E et al (2010) The formation of autoantibodies and antibodies to TNF-\u03b1 blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 28:661\u2013668","journal-title":"Clin Exp Rheumatol"},{"key":"3428_CR10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/ard.2008.089979","volume":"68","author":"MK Vries de","year":"2009","unstructured":"de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ et al (2009) Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 68:531\u2013535","journal-title":"Ann Rheum Dis"},{"key":"3428_CR11","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1002\/art.23044","volume":"56","author":"RG Lambert","year":"2007","unstructured":"Lambert RG, Salonen D, Rahman P, Inman RD, Wong RL, Einstein SG et al (2007) Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 56:4005\u20134014","journal-title":"Arthritis Rheum"},{"key":"3428_CR12","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/ard.2009.111187","volume":"69","author":"SJ Pedersen","year":"2010","unstructured":"Pedersen SJ, S\u00f8rensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS et al (2010) Responsiveness of the ankylosing spondylitis disease activity score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 69:1065\u20131071","journal-title":"Ann Rheum Dis"},{"key":"3428_CR13","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3899\/jrheum.091043","volume":"37","author":"WP Maksymowych","year":"2010","unstructured":"Maksymowych WP, Salonen D, Inman RD, Rahman P, Lambert RG, CANDLE Study Group (2010) Low-dose infliximab (3\u00a0mg\/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. J Rheumatol 37:1728\u20131734","journal-title":"J Rheumatol"},{"key":"3428_CR14","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J et al (2009) The development of Assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777\u2013783","journal-title":"Ann Rheum Dis"},{"key":"3428_CR15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1515\/cclm-2013-0461","volume":"51","author":"B Ruiz-Arg\u00fcello","year":"2013","unstructured":"Ruiz-Arg\u00fcello B, del Agua AR, Torres N, Monasterio A, Mart\u00ednez A, Nagore D (2013) Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med 51:287\u2013289","journal-title":"Clin Chem Lab Med"},{"key":"3428_CR16","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1136\/ard.2009.110767","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Jurik AG, Hermann KG, Landew\u00e9 R, van der Heijde D, Baraliakos X et al (2009) Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS\/OMERACT MRI group. Ann Rheum Dis 68:1520\u20131527","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-016-3428-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-016-3428-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-016-3428-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T07:28:35Z","timestamp":1559028515000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-016-3428-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,27]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["3428"],"URL":"https:\/\/doi.org\/10.1007\/s00296-016-3428-0","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,27]]}}}